Evaluation of the Proportion of SARS-CoV-2 IgG Antibodies in those Who Received the Coronavirus Vaccine Compared to Those Who had Previous Infections

Of a total of 30 cases collected divided into three groups Including 10 (33.3 %) were participants who had received two doses vaccinated against the Coronavirus, the second groups10 (33.3 %) were people who have had a previous infection with Coronavirus and had received two doses vaccinated and the third groups10 (33.3 %) were the people who have only had a previous infection with the Coronavirus.

The results revealed high significance (p<0.05) in the specific IgG antibodies to anti- SARS-CoV-2 in the first group represented by individuals who took two dosages vaccinated against the Coronavirus When compared with the standard criteria used in the diagnostic kit used in the research (MAGLUMI 2019-nCoV IgG). This group included 10, which showed 10 (100%) the efficiency of the vaccines used against the Coronavirus has a significant IgG anti-SARS-CoV-2 concentration (positive) while there is no negative sample.

The present study revealed high significance (p<0.05) in the specific IgG antibodies to anti- SARS-CoV-2 in the second group represented by where those who have already been infected a previous with Coronavirus and had been received two doses of vaccination When compared to the diagnostic kit's conventional criteria, this group included 10, which showed 9 (90%) the efficiency of the vaccines used against the Coronavirus has a significant IgG anti-SARS-CoV-2 concentration (positive) while only 1 (10%) of the sample was negative, while the last group showed the percentage of acquired immunity specific IgG antibodies to anti- SARS-CoV-2 in people who have had a previous infection with the Coronavirus is a small percentage were 4 (40%)positive and 6 (60%) were negative.

The results of this research showed that high significance (p<0.05) in the specific IgG antibodies to anti- SARS-CoV-2 in the female in the first and second groups compared with a male which represented Individuals who took two doses vaccinated against the Coronavirus and people who have had a previous infection with Coronavirus and had been vaccinated respectively while in the third group the male showed high significance (p<0.05) compared to female which those who have already been infected a previous with Coronavirus.Finelly when compare between the vaccine which received in two doses.

Showed efficiency of the Pfizer vaccine (17.72) AU/mL compared to the Sinopharm vaccine (8.55 AU/)mL. Measurement was made in the first group only, which received vaccines in two doses and the rates were compared with the standard ratios of the kit used in the research.